Immunotherapy Research Antibodies

Diagram of clinically relevant immunotherapy target proteins and ligands on the surface of a cell.

Our antibodies target many of the most clinically relevant proteins in cancer immunotherapy, including PD-1, VISTA (PD-1H), OX40, and more.

In the dynamic realm of cancer immunotherapy research, antibodies play a pivotal role in unraveling the intricacies of immune cell regulation. This article delves into the significance of cancer immunotherapy antibodies, particularly in the context of antibody therapeutics, and explores their applications in the evolving landscape of cancer research and treatment.

As the field continues to advance, with an increasing number of monoclonal antibody therapies entering clinical trials each year, researchers demand ever more advanced tools to tap into the full potential of immunotherapy. Recognizing this need, our team at Absolute Antibody has harnessed recombinant antibody technology to develop a comprehensive collection of engineered recombinant antibodies. These antibodies specifically target clinically relevant proteins, including mouse homologs of current therapeutic targets that have been engineered for optimal in vivo performance, as well as bispecific antibodies, providing researchers with cutting-edge tools to propel cancer immunotherapy research forward.

Full List of Immunotherapy Antibodies Here

Antibodies Against Proteins in Immune Cell Regulation

The targeted development of antibodies against key proteins in immune cell regulation, including CTLA-4, PD-1, PD-L1, OX40, and GITR, holds immense promise for advancing cancer immunotherapy. These proteins, among the most searched and cited targets, play pivotal roles in modulating immune responses. Precise antibodies designed to interact with them offer groundbreaking therapeutic potential by regulating immune cell activation and function.

Understanding Cancer Immunotherapy

What is Cancer Immunotherapy?

At the forefront of advanced cancer treatments are FDA-approved monoclonal antibodies for cancer treatment, revolutionizing the field of cancer immunotherapy. Simply put, cancer immunotherapy harnesses the body’s immune system to fight cancer, and monoclonal antibody-based therapeutics play a key role in this approach. These targeted therapies are designed to specifically recognize and attack cancer cells, offering a precise and effective means of treating various forms of cancer.

How Does Cancer Immunotherapy Work?

Cancer immunotherapy operates by leveraging the body’s immune system to target and eliminate cancer cells, with monoclonal antibody therapies playing a crucial role in this process. These antibodies are designed to recognize specific proteins on cancer cells, acting as immune system boosters. For instance, FDA-approved monoclonal antibodies like pembrolizumab (Keytruda) and rituximab (Rituxan) work by blocking immune checkpoints or directly targeting cancer cells, promoting immune response and inhibiting cancer growth. This targeted approach enhances the body’s ability to identify and destroy cancer cells, marking a paradigm shift in cancer treatment strategies.

Why Immunotherapy Instead of Chemotherapy?

Immunotherapy offers distinct advantages over traditional chemotherapy, providing a targeted and precise approach to cancer treatment. Unlike chemotherapy, which can affect both cancerous and healthy cells, immunotherapy specifically harnesses the immune system to target cancer cells, minimizing collateral damage. This targeted nature of immunotherapy not only enhances treatment effectiveness but also reduces the severe side effects often associated with chemotherapy, representing a significant advancement in cancer care.

Types of Cancer Immunotherapy

Advancements in cancer care are driven by the targeted application of monoclonal antibodies in immunotherapy, showcasing tailored precision in prostate, colorectal, breast, and lung cancer treatments. Key players targeting specific aspects of cancer include antibodies against human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1), underscoring the potential to revolutionize treatment strategies across these diverse cancer types. 

Immunofluorescent assay with strong signal using the anti-PD-1 antibody clone RMP1-14

Anti-PD-1 (RMP1-14)

Immunofluorescent staining of mouse splenocytes. This antibody has been chimerized from its original rat IgG2a format to mouse IgG2a and includes Fc Silent™ engineering for tailored performance in vivo.

Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)]

IHC staining of paraffin-embedded human breast tissue. This antibody is a recombinant research-grade biosimilar available in variety of species and formats, including the original human IgG1 and species-swapped mouse IgG2a.

Anti-TNF alpha [cA2 (Infliximab)]

Western Blot using anti-TNF alpha Human IgG1 antibody in human thyroid tumor (lane 5). This antibody is available in a variety of species and formats.

Prostate Cancer

The application of monoclonal antibodies for prostate cancer treatment showcases promising developments in immunotherapy. Notably, anti-human epidermal growth factor receptor-2 (HER2) MAb trastuzumab, anti-epidermal growth factor receptor (EGFR) MAbs cetuximab and panitumumab, and antivascular endothelial growth factor (VEGF) MAb bevacizumab have emerged as key players in targeting specific aspects of prostate cancer. Trastuzumab targets HER2-positive prostate cancer cells, while cetuximab and panitumumab focus on inhibiting EGFR, disrupting cancer cell signaling. Additionally, bevacizumab, an anti-VEGF monoclonal antibody, curtails blood supply to the tumor. These tailored applications underscore the potential of monoclonal antibodies in providing precise and effective treatments for prostate cancer.

Colorectal Cancer

The application of monoclonal antibodies for colon cancer treatment has shown promising results in the realm of immunotherapy. Specifically designed monoclonal antibodies, such as cetuximab and bevacizumab, target key proteins involved in colon cancer progression. Cetuximab, an FDA-approved monoclonal antibody, inhibits the epidermal growth factor receptor (EGFR), impeding cancer cell growth. Additionally, bevacizumab, another monoclonal antibody approved for colon cancer, targets vascular endothelial growth factor (VEGF), curtailing blood supply to the tumor. These targeted applications showcase the potential of monoclonal antibodies in providing tailored and effective treatments for colon cancer.

Breast Cancer

The use of breast cancer monoclonal antibodies in immunotherapy represents a significant advancement in breast cancer treatment. Notably, anti-human epidermal growth factor receptor-2 (HER2) MAb trastuzumab and anti-programmed cell death protein 1 (PD-1) MAb pembrolizumab have emerged as key players in targeting specific aspects of breast cancer. Trastuzumab addresses HER2-positive breast cancer, while pembrolizumab, an immune checkpoint inhibitor, activates the immune response against cancer cells. These focused applications underscore the precision and effectiveness of breast cancer monoclonal antibodies in advancing immunotherapeutic approaches.

Lung Cancer

The specific applications of immunotherapy antibodies in lung cancer treatment have brought notable advancements to the forefront of cancer care. Monoclonal antibodies such as anti-programmed cell death protein 1 (PD-1) MAb pembrolizumab and anti-programmed cell death ligand 1 (PD-L1) MAb atezolizumab have shown promise in targeting lung cancer. Pembrolizumab, as an immune checkpoint inhibitor, unleashes the body’s immune response against cancer cells by blocking PD-1, while atezolizumab targets PD-L1 to disrupt immune evasion. These precise applications of immunotherapy antibodies in lung cancer underscore their potential to revolutionize treatment strategies and improve outcomes for patients.

Empowering Cancer Immunotherapy Research

Absolute Antibody is devoted to creating the best tools for research, especially in the field of immunotherapy. Here are the product collections, educational resources, and case studies we have to power cancer immunotherapy research.

Immunotherapy Antibodies by Absolute Antibody

Absolute Antibody has spearheaded the development of a collection of recombinant engineered antibodies against clinically relevant proteins. Tools available to empower cancer immunotherapy research include:

  • VivopureX™ Antibodies: These recombinant antibodies are engineered for improved in vivo performance in live mouse models, with Fc silencing and isotype switching for tailored therapeutic effects, and matched antibody species for reduced immunogenicity and longer serum half-life.
  • Research-Grade Biosimilars: We offer research-grade biosimilars to grant access to research tools for the study and evaluation of biological processes without the need to source and purchase costly therapeutic-grade biologics. Our immunotherapy antibodies are engineered from the original human species into mouse, rabbit, rhesus monkey, and cynomolgus monkey formats for added research potential.
  • Bispecific Antibodies: Engage two distinct targets with one antibody reagent with our range of recombinant engineered murine bispecific antibodies. Our collection offers high purity, low immunogenicity, and tailored effector function for in vivo applications in mouse models. Our antibody engineers can also custom engineer any bispecific antibody you can imagine.
  • Tumor Marker Antigens: Antibodies that target tumor markers can enhance cancer treatment and diagnosis. Benefit from our selection of recombinant engineered tumor marker antibodies, with 100% biological definition, Fc Silent™ formats for eliminated ADCC, and a variety of species and isotypes available to better address your research needs.

Immunotherapy Antibodies Resources

Below find more information on how our engineered recombinant antibodies enable better immunotherapy research, including the potential uses and cited applications for VivopureX™ antibodies against a variety of clinically relevant cancer research targets.

White Paper

A Question of Isotype: How Switching Antibody Isotypes and Fc Regions Promotes Discovery

How do you choose the right antibody format for your project beyond simply matching antibody and antigen? This white paper provides a discussion of how to select the right antibody format for your cancer research in live mouse models.

Case Studies

PD-1 Fc Silent™ Antibody Improves Anti-Tumor Activity in Mice

Researchers at UC Louvain developed a monoclonal antibody blocking GARP:TGF-β1, demonstrating promise in inducing anti-tumor activity. Combining this antibody with the Fc Silent™ anti-PD-1 antibody enhances tumor rejection in mouse models, showcasing a proof-of-concept for potential clinical applications and prompting a first-in-human phase I clinical trial.

Using Bispecific Antibody Reagents to Further Immunotherapy Research

Leiden University Medical Center (LUMC) researchers investigated oncolytic viruses’ synergy with bispecific T-cell-engaging antibodies created in collaboration with our engineers to enhance immunotherapy for solid tumors, demonstrating significant tumor regression and prolonged survival in mouse models.

Research Posters

Consistent, long-term PD1 blockade using a syngeneic, engineered anti-PD1 antibody

Our case study compared VivopureX™ syngeneic mouse IgG2a Fc Silent™ anti-mouse PD-1 antibodies to the original rat IgG2a version. Our engineered VivopureX™ antibody showed better dose efficacy and more homogenous treatment responses, reducing tumor size in mouse models more effectively than the traditional rat monoclonal antibody.

 

Fully murine knob-into-hole bispecific as surrogate molecule for drug development models

This poster reports the generation of a fully murine, knob-into-hole (KIH), heavy-chain heterodimerizing, bispecific antibody format—the first commercially available production platform of its kind. Additionally, it characterizes an anti-mCD3ε:TRP-1 bispecific antibody, capable of selectively recruiting T-cells to TRP-1+ cancer cells for increased cytotoxic effector function.

 

Comparing potential bispecific formats comprising of trastuzumab and a humanized OKT3

At Absolute Antibody, we have produced more than 180 different engineered antibody formats. In this case study, we have taken two well-studied monoclonal antibodies and we have shown that not all bispecific formats are created equal.

 

Product Features

Anti-PD-1H (MH5A)

Immunofluorescence staining of fixed mouse splenocytes with anti-PD-1H antibody MH5A (Ab01016). This antibody is available in a variety of formats, including multiple mouse IgG subtypes and rabbit IgG.

Anti-CTLA-4 (9D9)

Immunofluorescence staining of mouse splenocytes using anti-CTLA-4 antibody (Ab01018) 9D9. This antibody is available in rabbit IgG and a variety of mouse formats, including multiple IgG subtypes, Fab fragments, and bispecific formulations.

Anti-PD-1 (29F.1A12)

Immunofluorescence staining of mouse splenocytes with anti-PD-1 (Ab02816) 29F.1A12. This antibody is available in multiple mouse IgG subtypes, rat IgG2a and rabbit IgG. Find also antibodies with Fc Silent™ engineering.

  • PD-1: The target of several commercially available therapies either approved or under review, the anti PD-1 antibody is a promising tool for cancer research and therapeutic development.
  • PD-L1 and PD-L2: This article reviews the therapeutic potential of antibodies that target programmed death ligands, like PD-L1 inhibitors.
  • VISTA: Also known as PD-1H, VISTA is another immune checkpoint inhibitor of interest for cancer immunotherapy. Our article reviews the experimental potential of our engineered anti-VISTA antibodies.
  • TIGIT: Many tumors use the TIGIT checkpoint to evade anti-cancer immune responses. Our TIGIT antibody engineering expands the study of this pathway with new research potential.
  • CD47: Our antibody engineers have created a range of engineered recombinant antibodies targeting CD47, helping researchers elucidate how cancer cells exploit immune checkpoints and new therapeutic targets.

Other Immunotherapy Research Products

As an Absolute Biotech company, we are proud to combine our recombinant portfolio with our sister brands to expand your research possibilities with a wider array of antibodies and reagents.  

The critical role of immunotherapy research antibodies in advancing cancer treatments is clear: the right tools can open a wide range of experimental possibilities. With technology like Fc Silent™ mutations to abrogate Fc region binding, species swapping for optimized in vivo performance, and the generation of bispecific antibodies, the wealth of problem-solving capabilities offered by recombinant antibodies is endless. By providing researchers with sophisticated tools like these, the field continues to make strides towards more effective and personalized immunotherapeutic solutions. If your unique research needs have yet to be met by the off-the-shelf antibodies that we have available, we offer custom services such as antibody engineering. For inquiries or quotes, please reach out. Our team of antibody experts is happy to help you.

Immunotherapy Research Antibodies

Catalog IDMouse TargetAntibody Clone
Ab00110CD134OX86
Ab00111CD200ROX131
Ab00166CD8 alpha/Lyt-2YTS 169.4
Ab00205CD4 epitope AYTS 177.9
Ab00206CD4 epitope AYTS 191.1
Ab00295Ly6G1A8
Ab00584CD22OX-97
Ab00813PD-1RMP1-14
Ab00883PD-L2TY25
Ab00895CD27RM27-3E5
Ab01017PD-1Hmam82
Ab01018CTLA-49D9
Ab01026HVEMHMHV-1B18
Ab01027BTLAHMBT-6B2
Ab01028CD80RM80
Ab01030Ly6G/Ly6CRB6-8C5
Ab01031CD45RRA3-6B2
Ab01032Tim-13B3
Ab01057Tim-32C12
Ab01058Tim-45G3
Ab01059Tim-43A1
Ab01060GITRDTA-1
Ab01088Galectin 9RG9-35
Ab01089CD153RM153
Ab01092TIM-2RMT2-14
Ab01107CD25PC-61.5.3
Ab01108IFN-gamma receptor 1GR20
Ab01110CD2018B12
Ab01258TIGIT1B4
Ab01295LAG-3C9B7W
Ab01297CD966A6
Ab01298CD1553F1
Ab01366CD22610E5
Ab01417PD-1J43
Ab01419PD-L110F.9G2
Ab01420VISTA13F3
Ab01489CD196D5
Ab01490IL-10R1B1.3a
Ab01491CD115/M-CSFRAFS98
Ab01569CD47mIAP301
Ab02816PD-129F.1A12
Ab00105CD3 epsilon145-2C11
Ab00109Thy1.1OX7
Ab00147IL-411B11
Ab00208CD5YTS 121.5.2
Ab00212Thy-1YTS 154.7.7.10
Ab00236Complement Receptor 1 & 27G6
Ab00278Nerve Growth FactoralphaD11
Ab00620CD62LMEL-14
Ab00621MAdCAM-1MECA-367
Ab00449alpha 5 beta 1/α5β1 IntegrinM200 (Volociximab)
Ab00296C5Eculizumab
Ab00281CEAArcitumomab
Ab04187CCL11CAT-213 (Bertilimumab)
Ab04182CCR2MLN1202 (Plozalizumab, hu1D9)
Ab00726CCR4KW-0761 (Mogamulizumab)
Ab04183CD105TRC105 (Carotuximab)
Ab00535CD11ahu1124 (Efalizumab)
Ab01678CD154IDEC-131 (Toralizumab)
Ab00126CD2010F381 (rituximab)
Ab00728CD22hL22 (Epratuzumab)
Ab00194CD25YTH 906.9HL (Campath-6)
Ab00958CD257BAFF (Tabalumab)
Ab00122CD3 epsilonOKT-3 (muromonab)
Ab00283CD33hP67.6 (Gemtuzumab)
Ab00730CD33SGN-33 (Lintuzumab)
Ab00450CD4CE9.1 (Clenoliximab)
Ab00217CD4MT310
Ab00167CD4YNB46.1.8 (Campath-9H)
Ab00447CD40Lhu5c8 (Ruplizumab)
Ab00282CD417E3 (Abciximab)
Ab04186CD49BGBR500 (Vatelizumab, TMC-2206)
Ab00124CD52Alemtuzumab (Campath-1H)
Ab00165CD52YTH 34.5-G2b (Campath-1G)
Ab00736CD80IDEC-114 (Galiximab)
Ab00898CD98EP3-1
Ab00740DR5PRO95780 (Drozitumab)
Ab01677EGFRZalutumumab; HuMax-EGFR
Ab00279EGFRC225 (Cetuximab)
Ab00534EGFRMatuzumab
Ab00723EGFR domain IIIh-R3 (Nimotuzumab)
Ab00103erbB-2 (Her-2/neu)4D5-8 (trastuzumab)
Ab04184FAP alphaBIBH1 (Sibrotuzumab, huF19)
Ab00802FasR-125224
Ab03043FOLR1Farletuzumab (MORAb-003; M3)
Ab00717IgEhuMaE11 (Omalizumab)
Ab00722IL-12/23ABT-874 (Briakinumab)
Ab03711IL-20h15D2 (Fletikumab)
Ab00187IL-2RDaclizumab
Ab00188IL-2R alphaBasiliximab
Ab04155IL-5SB-240563 (Mepolizumab)
Ab04156IL-5Sch 55700 (Reslizumab)
Ab00737IL-6 receptorrhPM-1 (Tocilizumab)
Ab00716Integrin alpha 4Natalizumab
Ab04181Integrin alpha-4/beta-7Vedolizumab (LDP-02)
Ab00773Lymphotoxin alphaMLTA3698A (Pateclizumab)
Ab00536OX40LR4930 (Oxelumab)
Ab01274oxLDL2-DO3
Ab00791PD-15C4.B8 (Nivolumab)
Ab00729RSVRSHZ19 (Felvizumab)
Ab01147TAG-72Minretumomab (CC49 )
Ab00742TenascinI-81C6 (Neuradiab)
Ab00146TNF alphacA2 (Infliximab)
Ab00448TNF alphaCDP 571 (Humicade)
Ab00718TNF alphaD2E7 (Adalimumab)
Ab00180TRP-1, gp75TA99
Ab00280Tumor associated glycoprotein (TAG) 72B72.3 (Satumomab)
Ab00846V(beta)3 TCRJOVI.1
Ab00715VEGFBevacizumab
Ab04185Amyloid beta A4 proteinLY2062430 (Solanezumab, hu266)
Ab010524-1BB (CD137)LOB12.3
Ab010544-1BBL (CD137L)AT113-2
Ab008814-1BBL (CD137L)TKS-1
Ab01027BTLAHMBT-6B2
Ab00670CD27LG.3A10
Ab00895CD27RM27-3E5
Ab00286CD28E18
Ab00285CD28D665
Ab01109CD4045374
Ab01087CD40L (CD154)MR1
Ab00816CD70TAN 1-7
Ab01056CD70TAN1-6
Ab01028CD80 (B7-1)RM80
Ab01029CD86 (B7-2)PO.3
Ab01089CD153RM153
Ab01297CD966A6
Ab00894CTLA-49H10
Ab01018CTLA-49D9
Ab01088GAL-9RG9-35
Ab01060GITRDTA-1
Ab00374GITRYGITR 860.103.5
Ab00631GITRYGITR765
Ab00630GITRLYGL386
Ab01026HVEMHMHV-1B18
Ab00814ICOS7E.17G9
Ab00882ICOSLHK5.3
Ab01295LAG3C9B7W
Ab00110OX40 (CD134)OX86
Ab00564OX40LOX-89
Ab00813PD-1RMP1-14
Ab01017PD-1H (VISTA)mam82
Ab01016PD-1H (VISTA)MH5A
Ab00373PD-L1YDC 127.1.1
Ab00883PD-L2TY25
Ab00875PDPN (MAP-Tag)PMab-1
Ab00973TIGIT4D4
Ab01258TIGIT1B4
Ab01032TIM-13B3
Ab01110TIM-2RMT2-14
Ab01057TIM-32C12
Ab01058TIM-45G3
Ab01059TIM-43A1
bAb0249CD19xCD3e6D5 x 145-2C11
bAb0185CD20xCD3e18B12 x 145-2C11
bAb0166CTLA-4xPD-L19D9 x VHH-PD-L1
Ab01018-1.169CTLA-4xOX409D9 x OX86
bAb0163EGFRxCD3eC225 (Cetuximab) x 145-2C11
bAb0164EGFRvIIIxCD3eL8A4 x 145-2C11
bAb0162erbB-2 (Her-2/neu)xCD3e4D5-8 (trastuzumab) x 145-2C11
bAb0183erbB-2 (Her-2/neu)xCD3e4D5-8 (trastuzumab) x OKT3
bAb0184F4/80xCD3erecombinant Cl:A3-1 x 145-2C11
bAb0161FluoresceinxCD3e4-4-20 (enhanced) x 145-2C11
bAb0168FluoresceinxPD-L14-4-20 (enhanced) x VHH-PD-L1
bAb0167FluoresceinxCD474-4-20 (enhanced) x A4
bAb0136TRP-1, gp75 x CD3eTA99 x 145-2C11
bAb0165TRP-1, gp75 x CD47TA99 x A4
bAb0182TRP-1, gp75 x OX40TA99 x OX86
Ab00542-1.68CD200 x CD47OX-90
Ab00813-1.69PD-1 x PD-L1RMP1-14
Ab00813-1.68PD-1 x CD47RMP1-15
bAb0615PD-L1 x CD3e10F.9G2 x 145-2C11
Ab00373-1.68PD-L1 x CD47YDC 127.1.1
Ab01419-1.169PD-L1 x OX4010F.9G2 x OX86
bAb0653PD-L1 x CD2810F.9G2 x D665
Ab01017-1.69PD-1H x PD-L1mam82
Ab00973-1.69TIGIT x PD-L14D4
bAb0505NKG2D x CD3eCX-5 x 145-2C11
Ab00782A33huA33
Ab00213Alpha-fetoprotein (AFP)AF5
Ab02189Alpha-ketoglutarate-dependent dioxygenase alkB homolog 332C8_71
Ab03472Aspartate beta-hydroxylaseG3-F11
Ab01321BCL2bcl-2/100
Ab00181Beta-2 microglobulinBBM.1
Ab01322BLC2bcl-2/124
Ab00380Breast Epithelial MucinBrE-3
Ab01215c-erbB-2FWP51
Ab00525CA125196-14
Ab02836CA125OC125-3.11
Ab02835CA125VK-8-1.9
Ab03769CA19-94A6
Ab03770CA19-94G2
Ab03766CA242C242
Ab03768CA50CA50Ab01
Ab02092Canine LymphomaMab231
Ab00281carcinoembryonic antigen (CEA)Arcitumomab
Ab01165carcinoembryonic antigenA5B7
Ab03901CD155CD155.16
Ab03902CD155scFv1
Ab03903CD155scFv3
Ab03739CD155SKII.4
Ab02210CD19B4
Ab02064CEABW431/26
Ab02721CEACH1A1A (2F1, CH1A1A-2F1)
Ab01002CEAEB-011
Ab01003CEAEB-022
Ab02833CEAT84.66
Ab02587CIP2AHL1925
Ab01683CSApMu-9
Ab00616Ctip225B6
Ab01648Cytokeratin 7OV-TL 12/30
Ab03179Cytokeratin 8TS1
Ab00822deltaEGFRDH8.3
Ab01677EGFR2F8 (Zalutumumab; HuMax-EGFR)
Ab02461EGFR2224
Ab00133EGFR528
Ab00279EGFRC225 (Cetuximab)
Ab03275EGFRcet.Hum (Cetuximab – humanized; hC225)
Ab00608EGFREGFR1
Ab00453EGFRL2 1C
Ab00455EGFRL3 11D
Ab00534EGFRMatuzumab
Ab00452EGFRS3 12D
Ab00454EGFRS4 10H
Ab00723EGFR domain IIIh-R3 (Nimotuzumab)
Ab00184EGFRvIIIL8A4
Ab03195EndosialinscFv78
Ab01197EPCAMB38.1
Ab00103erbB-2 (Her-2/neu)4D5-8 (trastuzumab)
Ab00303ERBB2SAIC-02A-7
Ab00515GA733-2FU-MK-1
Ab03700GDF15Clone 29
Ab03701GDF15MBM-12
Ab03702GDF15MBM-14
Ab03427Glypican-1AbAb-GPC1
Ab01093HER24D5
Ab00924HER2C7b
Ab02462HER2ML3-9 (C6ML3-9)
Ab00383HER2/neuSER4
Ab02460HER3A5
Ab02661HER4B6 (HER4.B6)
Ab01485high MWT epithelial antigensKC4G3
Ab00430Human Ephrin Type A receptor 21C1
Ab03260JAM-A6F4
Ab03878KRAS G12C mutantAbAbKRAS01
Ab03877KRAS G12D mutantD113
Ab01227Lewis Y3S193
Ab00492LeYBR96
Ab00493LeYH18A
Ab00761LMP1H3
Ab01565m5CFMC-9
Ab02838MAGEA321B4
Ab02080Mesothelin11-25
Ab02078MesothelinC10
Ab02081MesothelinIC14-30
Ab02079MesothelinK1
Ab02082MPF20-10
Ab02083MPF41-28
Ab01329MUC1E29
Ab02206MUC1HMFG1 (1.10.F3)
Ab00712MUC1HMFG2
Ab00345MUC1Mc5
Ab02454MUC1PAM4
Ab00215MUC1SM3
Ab03096NSEE1-7E2
Ab03097NSEE2-4F6
Ab00512OA3OV-TL3
Ab01168osteosarcoma-associated cell membrane antigenTP-1
Ab01167osteosarcoma-associated cell membrane antigenTP-3
Ab00923p21Y13-238
Ab03876p21RasDWP
Ab03875p21RasKGH-R1
Ab00142p53PAb421
Ab01166polymorphic epithelial mucinCTM01
Ab00423PSA8G8F5
Ab00435PSAscFv B8
Ab03135PSMA11d1e5E10
Ab03969PSMA8C12
Ab03136PSMAJ591
Ab01325S100S1-61
Ab02453S100B1C8
Ab00301SynaptophysinSP15
Ab01147TAG-72Minretumomab (CC49)
Ab00742TenascinI-81C6 (Neuradiab)
Ab00382Tn Antigen237mAb
Ab00619trastuzumab (anti-idiotype)scFv40
Ab00618trastuzumab (anti-idiotype)scFv69
Ab00180TRP-1, gp75TA99
Ab00280Tumor associated glycoprotein (TAG) 72B72.3 (Satumomab)
Ab00169VAP-12D10
Ab02395VAP-13F10
Ab02394VAP-13G6
Ab00168VAP-1TK8-14